Initiative seeks innovative experimental and computational approaches to uncover neural circuits regulating immune function and identify novel therapeutic targets
The company plans an aggressive partnering push, with 62 pre-scheduled meetings over four days, focused on out-licensing, co-development, and strategic collaborations with global pharmaceutical and biotech players
The FDA has granted Priority Review, setting a target decision date of 9 October 2026, potentially accelerating access to a new treatment option for a subset of patients with high-risk colon cancer characterized
New Gurugram centre is India's first clinical Prevention Centre with 2 state of the art MRI machines and a capacity of 2000 scans a month
.jpeg)
One of our major priorities in next 3-5 years is the introduction of a kit-based version of CanAssist Breast, enabling hospitals conduct the test locally
Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships
The FDA nod marks a step forward in precision oncology, linking molecular diagnostics more tightly to therapy selection for advanced prostate cancer
New hit discovery service combines integrated DNA-Encoded Library screening, structural biology, biophysics, and X-ray crystallography
New Shoolagiri plant strengthens Maiva’s global CDMO capabilities with advanced isolator technology, flexible production lines, and expanded capacity for complex injectable therapies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
